Community pharmacy’s role in preventing fentanyl overdose deaths

Fentanyl has changed the risk of illicit drug use in Australia, turning substances that once appeared predictable into potentially lethal exposures. Potency and concentration can vary widely, and people may not know a supply contains fentanyl. Community pharmacists are well placed to respond because they are accessible, trusted and already involved in harm reduction, medication safety and referrals to treatment.

Fentanyl test strips offer a practical way to detect fentanyl in a sample before use. Used correctly, they can prompt earlier intervention, support informed choices and open conversations that might otherwise never happen. They complement naloxone rather than replace it, and their value depends on confidential counselling, reliable local pathways and a clear emergency response.

For Australian pharmacies, the task extends beyond handing over a test strip. Rules, funding and service availability differ across states and territories, while stigma can prevent people seeking help. A professional response must combine drug checking, take-home naloxone, treatment connections and follow-up care within a system designed to keep people alive.

Why fentanyl changes the risk profile

Fentanyl and its analogues can cause severe respiratory depression at very small doses. They have been detected in injected drugs, inhaled substances and counterfeit tablets, making visual inspection unreliable. Tolerance to heroin or other opioids does not necessarily protect someone from fentanyl, and a familiar supply can change without warning. A person may also take a substance believing it is something else, leaving them unprepared for a sudden loss of consciousness.

The consequences require rapid action. Naloxone can reverse opioid toxicity, but fentanyl may require repeated doses, and emergency care remains essential. People who use alone face additional danger because no one can recognise an overdose or call for help. Harm reduction therefore depends on practical connections: distributing naloxone, reducing isolation where possible, providing drug checking and linking people with treatment and peer support before a crisis occurs.

What a fentanyl test strip can tell you

A positive strip indicates that fentanyl has been detected in the tested sample. It does not measure the amount present, establish a safe dose or identify every other substance in the supply. Detection of some fentanyl analogues also varies between products. A negative result cannot guarantee safety because the sample may have been too small, poorly collected or tested outside the reliable reading period, while an unexpected substance may remain undetected.

Test strips should be used according to the manufacturer’s directions and the instructions supplied by the service. Pharmacists need training in sample handling, reading times, possible false results and safe disposal. Only the specified sample should be tested, and it must be kept separate from material intended for consumption. A positive result should trigger clear harm reduction advice rather than panic. A negative result should never be presented as permission to use an untested substance or as proof that an overdose cannot occur.

Building a confidential pharmacy service

Distribution works best when it operates as a structured clinical service, not an informal favour. Pharmacists should confirm current local rules, use approved products, document consent and maintain procedures for storage, counselling and disposal. Staff also need to know when an observation requires escalation and when another service is better placed to assist. Professional indemnity arrangements should be checked before expanding an activity beyond an established program.

Privacy is essential in a busy dispensary. Staff can offer testing and naloxone without implying that a customer has been identified as a “problem drug user”. A simple offer to everyone accessing relevant services can reduce stigma and reach people who would not describe themselves as regular substance users. Where privacy is limited, the pharmacist should explain how the conversation will be protected, any limits to confidentiality and the availability of peer workers or treatment referral.

Household safety is another valuable entry point. Parents of adolescents can receive guidance on medicine storage, safe disposal and explaining why prescription medicines should never be shared. A discussion of encouraging independent play provides a useful communication parallel: children are more likely to develop responsible judgement when adults offer practical tools rather than relying on warnings alone. Pharmacists can apply that principle to medicines, naloxone and emergency planning without alarming families.

Naloxone and emergency response in Australia

An opioid overdose may involve slowed or stopped breathing, blue or grey lips, pinpoint pupils and an inability to wake. Call 000, place the person on their side if they are breathing but unresponsive, and begin cardiopulmonary resuscitation if they are not breathing normally. Naloxone should be given without delay, following the product instructions and the ambulance dispatcher’s guidance. If there is no response, another dose may be needed after two to three minutes. Do not leave the person alone, and do not wait for naloxone to work without ensuring help is on the way.

Take-home naloxone makes this response possible before paramedics arrive. Intranasal products can be useful for bystanders who have never given an injection, while injection formulations remain important options. Training should cover recognition of overdose, device use, the need for repeat doses and the importance of calling an ambulance even when breathing improves. Where feasible, a person should practise with the device and ensure that household members know where it is kept. An unlocked door and accessible naloxone can make the difference during an emergency.

Post-overdose care is equally important. After stabilisation, the person should be connected with treatment, peer support and a primary healthcare provider, with consent and attention to privacy. Naloxone can save a life, but it does not remove the need for ongoing care. People leaving prison, hospital or residential treatment may have reduced tolerance, making a return to previous opioid doses particularly dangerous.

Australian partnerships, equity and local access

Australia already has practical examples of community pharmacy leadership. Melbourne’s Highpoint Pharmacy helped pioneer pharmacist-led fentanyl test strip distribution in 2019, demonstrating that drug checking could be incorporated into a working community pharmacy rather than confined to specialist services. In NSW, the Stay Safe program has placed peer workers and take-home naloxone in selected pharmacies, including sites serving Sydney and regional communities. These models show the value of combining a trusted retail setting with trained support workers and rapid clinical referral.

Other jurisdictions are developing their own pathways. Queensland’s Kirstie program has expanded access to naloxone and drug checking through participating services, including pharmacies in Brisbane and regional areas. Access still depends on program eligibility, site approval and current supply arrangements. Pharmacists should maintain up-to-date referral contacts rather than giving a person a telephone number without checking whether the service remains available.

Local market conditions also shape access. Many Australians can buy naloxone without a prescription from community pharmacies, including discount chains such as Chemist Warehouse and SuperPharm, although consumer-purchased naloxone generally sits outside Pharmaceutical Benefits Scheme subsidy. In regional and remote areas, travel distance, freight costs and limited staffing can create further barriers. Aboriginal community-controlled health services can provide culturally grounded alcohol and other drug care where mainstream services are less accessible. Implementation should respect local customs, community authority and the service preferences of Aboriginal and Torres Strait Islander communities.

Evidence, stigma and clinical responsibility

The evidence for drug checking and naloxone is strongest when the two are considered together. Naloxone has a well-established role in reversing opioid toxicity, while drug checking services can identify unexpected substances and connect clients with support before an overdose occurs. Evidence specific to fentanyl test strips and mortality remains more limited, so services should avoid promising prevention in every case. Their benefits are more plausibly found in earlier information, safer discussions and improved access to treatment.

The public advocacy of pharmacist and mental health advocate Johnathan Laird reinforces the value of treating people with dignity rather than defining them by problematic drug use. Lived experience, professional expertise and peer knowledge should complement one another, particularly when discussing dependence, trauma and suicide risk. Pharmacy teams should use non-stigmatising language, ask what support a person wants and avoid judgements that delay care.

Responsibility also extends to documentation, supervision and data governance. Consent should be obtained before recording information, and reporting should protect confidentiality while meeting legal and professional requirements. Staff need to know when a concern must be escalated, but routine substance use should not trigger unnecessary involvement of police, employers or family members. Clear boundaries protect both the client and the pharmacist.

Turning distribution into a sustainable safety net

Evaluation should measure more than the number of strips distributed. Useful indicators include naloxone supplied, overdose reversals reported, referrals accepted, clients returning for further support and whether pharmacy staff feel prepared. Results should be aggregated without identifying individuals, and stories should be shared only with explicit permission. A strip distribution record cannot establish how many deaths were prevented, but it can reveal whether people are reaching other services.

Sustainable funding is essential. Pharmacists should not be expected to absorb the costs of training, quality-assured products, stock monitoring and lengthy harm reduction consultations. Commonwealth, state and territory funding should support reliable supply and clear national expectations while allowing local pathways to remain responsive. Professional bodies, policymakers and pharmacy owners can help by treating overdose prevention as a core public health function rather than an optional extra.

Collaboration determines whether a test strip leads to lasting care. Pharmacists can work with opioid treatment programs, general practitioners, needle and syringe programs, mental health services, ambulance services and Aboriginal health organisations. Medication management reviews and home medicines reviews can also identify untreated pain, unsafe combinations, unused opioids and gaps in treatment. Post-overdose follow-up should be routine, particularly after hospital discharge or release from custody. Every part of this pathway must function if the central promise is to be kept: fewer fentanyl-related deaths and stronger support for people who use drugs.

Preventing overdose deaths requires more than a single device. Fentanyl test strips can reveal risk that was previously hidden, but their greatest value comes when they are connected to confidential advice, take-home naloxone, competent emergency care and continuing treatment. Community pharmacy teams can make that connection routinely, bringing lifesaving support into familiar and accessible places.

Ask your local community pharmacy about test strip access, take-home naloxone and referral pathways. Pharmacists, pharmacy owners, policymakers and consumers can help make these services available in every neighbourhood by supporting trained staff, funded supplies and non-stigmatising care.